Ikarian Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Ikarian Capital’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,500	Closed	-$3.63M	–	174
2023 Q3	$3.63M	Buy	+2,500	New	+$47.3K	0.44%	60
2021 Q1	–	Sell	-100,000	Closed	-$2.22M	–	331
2020 Q4	$2.22M	Buy	+100,000	New	+$2.07M	0.1%	149

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Ikarian Capital's SNDX Position: Q4 2025 in Review

Ikarian Capital sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 333,733 shares — an estimated $5.13M sold.

Ikarian Capital first reported a position in SNDX in Q2 2020 and held it in 5 quarters. The position peaked at $5.13M in Q3 2025. 229 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Ikarian Capital reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Ikarian Capital sold 333,733 Syndax Pharmaceuticals shares in Q4 2025, an estimated $5.13M.
Ikarian Capital first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 5 quarters.
Ikarian Capital's Syndax Pharmaceuticals position peaked at $5.13M in Q3 2025.
229 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.